No Data
Rhythm Pharmaceuticals Insider Sold Shares Worth $554,817, According to a Recent SEC Filing
Joseph Shulman, Chief Technical Officer, on July 16, 2024, sold 10,468 shares in Rhythm Pharmaceuticals (RYTM) for $554,817.
Rhythm Pharmaceuticals' (NASDAQ:RYTM) Growing Losses Don't Faze Investors as the Stock Surges 17% This Past Week
When you buy shares in a company, there is always a risk that the price drops to zero.
Morgan Stanley Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $55
Morgan Stanley analyst Jeffrey Hung maintains $Rhythm Pharmaceuticals(RYTM.US)$ with a buy rating, and maintains the target price at $55.According to TipRanks data, the analyst has a success rate of 5
Morgan Stanley Keeps Their Buy Rating on Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, July 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare
Wells Fargo Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $52
Wells Fargo analyst Derek Archila maintains $Rhythm Pharmaceuticals(RYTM.US)$ with a buy rating, and maintains the target price at $52.According to TipRanks data, the analyst has a success rate of 45.